{"product_id":"plasma-fractionation-market-by-product-immunoglobulins-albumin-protease-inhibitors-von-willebrand-factor-pcc-application-neurology-immunology-hematology-rheumatology-end-user-clinical-research-hospitals-clinics-global-forecast-to-2028","title":"Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals \u0026 Clinics) - Global Forecast to 2028","description":"\u003cp\u003ePlasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals \u0026amp; Clinics) - Global Forecast to 2028\u003c\/p\u003e\n\n\u003cp\u003eThe global plasma fractionation market size is projected to reach USD 40.4 billion by 2028 from USD 29.0 billion in 2023, at a CAGR of 6.9% during the forecast period. Expanding the number of plasma collection centers allows market players to collect a larger volume of plasma from donors. This increased supply of raw materials becomes the foundation for producing a greater quantity of plasma-derived products, meeting the growing demand in the market. For instance, in December 2022, CSL Behring (Australia) announced the opening of a USD 900 million Plasma Fractionation Facility in Victoria, Australia. The new state-of-the-art facility can process up to 9.2 million plasma equivalent liters per annum.\u003c\/p\u003e\n\n\u003cp\u003e“The hospitals and clinics segment is expected to dominate the market during the forecast period.”\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, the plasma fractionation market is segmented into research laboratories, hospitals and clinics, and academic institutes. In 2022, the clinics and hospitals segment accounted for the largest share of the global plasma fractionation market. The growing number of hospitals and clinics in emerging and developed economies, as well as the improvement in healthcare infrastructure, are attributed to this segment's major share in the market. Leading companies in this market are collaborating with hospitals to conduct clinical trials and promote awareness about the use of plasma products in the treatment of rare diseases. The demand for plasma products for the treatment of many rare and life-threatening disorders like hemophilia, PID, and COVID-19 is anticipated to increase as a result of such initiatives by companies and hospitals.\u003c\/p\u003e\n\n\u003cp\u003e“The pulmonology application segment will witness the highest growth in the plasma fractionation market.”\u003c\/p\u003e\n\n\u003cp\u003eBased on application, the plasma fractionation market is segmented into hematology, critical care, pulmonology neurology, immunology, , hemato-oncology, rheumatology, and other applications. In 2022, the pulmonology segment is expected to register the highest CAGR during the forecast period. The two major plasma products used in the treatment of various respiratory disorders are immunoglobulins and protease inhibitors. The main functions of immunoglobulins are the prevention and treatment of upper and lower respiratory tract infections. The market for pulmonology applications has grown significantly in recent years due to the significant growth in the usage of protease inhibitors, such as alpha-1-antitrypsin.\u003c\/p\u003e \n\n\u003cp\u003e“North America will dominate the market during the forecast period.”\u003c\/p\u003e\n\n\u003cp\u003eBased on region, the plasma fractionation market is further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2022, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. North America's dominance in the global market is due to the fact that top players are continuously engaged in adopting various organic and inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market position. Major players in this industry in the area use the expansion of fractionation plants with cutting-edge technologies as a key growth strategy. The top competitors also focus on acquiring plasma collecting facilities to increase their market share in North America.\u003c\/p\u003e \n\n\u003cp\u003eThe primary interviews conducted for this report can be categorized as follows:\u003c\/p\u003e\n\n\u003cp\u003eBy Respondent: Supply Side - 70% and Demand Type - 30%\u003c\/p\u003e\n\n\u003cp\u003eBy Designation: Managers - 45%, Directors - 30%, and Executives - 25%\u003c\/p\u003e\n\n\u003cp\u003eBy Region: North America -25%, Europe -25%, Asia-Pacific -40%, Latin America-5%, Middle East -2.5% \u0026amp; Africa- 2.5%\u003c\/p\u003e\n\n\u003cp\u003eList of Companies Profiled in the Report\u003c\/p\u003e \n\n\u003cp\u003eCSL (Australia)\u003c\/p\u003e\n\n\u003cp\u003eTakeda Pharmaceutical Company Limited (Japan)\u003c\/p\u003e\n\n\u003cp\u003eGrifols, S.A. (Spain)\u003c\/p\u003e\n\n\u003cp\u003eOctapharma AG (Switzerland)\u003c\/p\u003e\n\n\u003cp\u003eKedrion S.P.A (Italy)\u003c\/p\u003e\n\n\u003cp\u003eLFB (France)\u003c\/p\u003e\n\n\u003cp\u003eADMA Biologics (US)\u003c\/p\u003e\n\n\u003cp\u003eSanquin (Netherlands)\u003c\/p\u003e\n\n\u003cp\u003eChina Biologic Products Holdings Inc. (China)\u003c\/p\u003e\n\n\u003cp\u003eGC Pharma (Korea)\u003c\/p\u003e\n\n\u003cp\u003eHualan Bioengineering Co., Ltd. (China)\u003c\/p\u003e\n\n\u003cp\u003eJapan Blood Products Organization (Japan)\u003c\/p\u003e\n\n\u003cp\u003eEmergent BioSolutions (US)\u003c\/p\u003e\n\n\u003cp\u003eShanghai Raas Blood Products Co., Ltd. (China)\u003c\/p\u003e\n\n\u003cp\u003eIntas Pharmaceuticals Ltd. (India)\u003c\/p\u003e\n\n\u003cp\u003eBharat Serum Vaccines Limited (India)\u003c\/p\u003e\n\n\u003cp\u003eSK Plasma (Korea)\u003c\/p\u003e\n\n\u003cp\u003eSichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)\u003c\/p\u003e\n\n\u003cp\u003eKamada (Israel)\u003c\/p\u003e\n\n\u003cp\u003eCenturion Pharma (Istanbul)\u003c\/p\u003e\n\n\u003cp\u003eProthya Biosolutions (Netherlands)\u003c\/p\u003e\n\n\u003cp\u003ePlasmaGen BioSciences Pvt. Ltd. (India)\u003c\/p\u003e\n\n\u003cp\u003eVirchow Biotech Private Limited (India)\u003c\/p\u003e\n\n\u003cp\u003eFusion Healthcare (India)\u003c\/p\u003e\n\n\u003cp\u003eHemarus Therapeutics Limited (India)\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage:\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a detailed picture of the plasma fractionation market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.\u003c\/p\u003e\n\n\u003cp\u003eReasons to Buy the Report:\u003c\/p\u003e \n\n\u003cp\u003eThe report provides insights on the following pointers:\u003c\/p\u003e\n\n\u003cp\u003eAnalysis of key drivers (growing use of immunoglobulins in various therapeutic areas, strategic expansion of plasma collection centers\/inventories by market players, growing prevalence of respiratory diseases and AATD), restraints (high costs and limited reimbursements for plasma products, market disruption caused by recombinant alternatives), opportunities (government strategies increasing regional self-sufficiency), and challenges (stringent government regulations for maintaining safety and quality of plasma products) influencing the growth of the plasma fractionation market.\u003c\/p\u003e\n\n\u003cp\u003eProduct Development\/Innovation: Detailed insights on upcoming technologies, research \u0026amp; development activities, and new product launches in the plasma fractionation market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various plasma fractionation facilities across key geographic regions.\u003c\/p\u003e\n\n\u003cp\u003eMarket Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionation market.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Assessment: In-depth assessment of market ranking and strategies of the leading players like CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), among others in the plasma fractionation market.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 374 Pages \/ MCW16232348","offer_id":47647494013234,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/plasma-fractionation-market-by-product-immunoglobulins-albumin-protease-inhibitors-von-willebrand-factor-pcc-application-neurology-immunology-hematology-rheumatology-end-user-clinical-research-hospitals-clinics-global-forecast-to-2028","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}